Free Trial

uniQure (QURE) Stock Price, News & Analysis

uniQure logo
$14.84 -1.65 (-10.01%)
Closing price 04:00 PM Eastern
Extended Trading
$15.18 +0.34 (+2.26%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About uniQure Stock (NASDAQ:QURE)

Key Stats

Today's Range
$14.71
$16.61
50-Day Range
$13.28
$17.95
52-Week Range
$4.45
$19.18
Volume
2.99 million shs
Average Volume
866,616 shs
Market Capitalization
$814.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.45
Consensus Rating
Buy

Company Overview

uniQure Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
64th Percentile Overall Score

QURE MarketRank™: 

uniQure scored higher than 64% of companies evaluated by MarketBeat, and ranked 385th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    uniQure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

  • Upside Potential

    uniQure has a consensus price target of $37.45, representing about 152.4% upside from its current price of $14.84.

  • Amount of Analyst Coverage

    uniQure has only been the subject of 3 research reports in the past 90 days.

  • Read more about uniQure's stock forecast and price target.
  • Earnings Growth

    Earnings for uniQure are expected to grow in the coming year, from ($3.75) to ($3.10) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of uniQure is -3.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of uniQure is -3.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about uniQure's valuation and earnings.
  • Percentage of Shares Shorted

    17.34% of the float of uniQure has been sold short.
  • Short Interest Ratio / Days to Cover

    uniQure has a short interest ratio ("days to cover") of 8.1.
  • Change versus previous month

    Short interest in uniQure has recently decreased by 6.89%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    uniQure does not currently pay a dividend.

  • Dividend Growth

    uniQure does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.34% of the float of uniQure has been sold short.
  • Short Interest Ratio / Days to Cover

    uniQure has a short interest ratio ("days to cover") of 8.1.
  • Change versus previous month

    Short interest in uniQure has recently decreased by 6.89%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    uniQure has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for uniQure this week, compared to 0 articles on an average week.
  • Search Interest

    26 people have searched for QURE on MarketBeat in the last 30 days. This is an increase of 271% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, uniQure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $322,426.00 in company stock.

  • Percentage Held by Insiders

    Only 4.79% of the stock of uniQure is held by insiders.

  • Percentage Held by Institutions

    78.83% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about uniQure's insider trading history.
Receive QURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

QURE Stock News Headlines

uniQure (NASDAQ:QURE) Earns "Buy" Rating from Chardan Capital
uniQure's (QURE) Buy Rating Reiterated at HC Wainwright
Buffett, Gates and Bezos Dumping Stocks
The world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century.tc pixel
uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript
uniQure Narrows Loss in Fiscal Q2
See More Headlines

QURE Stock Analysis - Frequently Asked Questions

uniQure's stock was trading at $17.66 at the beginning of the year. Since then, QURE shares have decreased by 16.0% and is now trading at $14.84.

uniQure N.V. (NASDAQ:QURE) released its earnings results on Tuesday, July, 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.20. The biotechnology company earned $5.26 million during the quarter, compared to analyst estimates of $5 million. uniQure had a negative net margin of 1,387.98% and a negative trailing twelve-month return on equity of 1,010.74%.
Read the conference call transcript
.

uniQure's top institutional investors include Vestal Point Capital LP (6.74%), Aberdeen Group plc (5.02%), Jefferies Financial Group Inc. (3.82%) and Nantahala Capital Management LLC (3.74%). Insiders that own company stock include Matthew C Kapusta, Christian Klemt, Ricardo Dolmetsch, Walid Abi-Saab, Jeannette Potts, Alexander Edward Kuta III, Pierre Caloz, Robert Gut, Madhavan Balachandran, Jeremy P Springhorn, David D Meek, Leonard E Post, Rachelle Suzanne Jacques, Jack Kaye and Paula Soteropoulos.
View institutional ownership trends
.

Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that uniQure investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

Last Earnings
7/29/2025
Today
9/15/2025
Next Earnings (Estimated)
11/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:QURE
CIK
1590560
Employees
500
Year Founded
1868

Price Target and Rating

High Price Target
$70.00
Low Price Target
$20.00
Potential Upside/Downside
+152.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.92)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$239.56 million
Net Margins
-1,387.98%
Pretax Margin
-1,375.80%
Return on Equity
-1,010.74%
Return on Assets
-33.27%

Debt

Debt-to-Equity Ratio
1.53
Current Ratio
9.98
Quick Ratio
9.98

Sales & Book Value

Annual Sales
$27.12 million
Price / Sales
30.02
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.14) per share
Price / Book
-106.00

Miscellaneous

Outstanding Shares
54,870,000
Free Float
52,239,000
Market Cap
$814.27 million
Optionable
Optionable
Beta
0.13

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:QURE) was last updated on 9/15/2025 by MarketBeat.com Staff
From Our Partners